CytomX Therapeutics, Inc. Unrecognized Tax Benefits, Income Tax Penalties Expense
CytomX Therapeutics, Inc. (CTMX) reported Unrecognized Tax Benefits, Income Tax Penalties Expense of $1.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties › Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense · last filed 2026-03-16
- CytomX Therapeutics, Inc. unrecognized tax benefits, income tax penalties expense for fiscal 2025 was $1.00M, a 0.00% change from fiscal 2024.
- CytomX Therapeutics, Inc. unrecognized tax benefits, income tax penalties expense for fiscal 2024 was $1.00M, a 0.00% change from fiscal 2023.
- CytomX Therapeutics, Inc. unrecognized tax benefits, income tax penalties expense for fiscal 2023 was $1.00M.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties Expense 12 month |
|---|---|
| 2025-12-31 | $1.00M 10-K · filed 2026-03-16 |
| 2024-12-31 | $1.00M 10-K · filed 2025-03-06 |
| 2023-12-31 | $1.00M 10-K · filed 2024-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |